HOWLWerewolf Therapeutics, Inc.

HOWL Stock Price, Valuation & Chart | Werewolf Therapeutics, Inc.

Compare

$1.000+0.04 (+4.26%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology HOWL intrinsic value HOWL calculated fair value vs price

Overview Financials Dividends Ratios

HOWL Historical price chart

HOWL Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization48.51M

PE Ratio-1.31

EPS-0.76

Trading Volume1.28M

Today's High/Low1.0/0.94

Dividend Yield0.00

52 Week High/Low2.38/0.27

Shares Outstanding48.60M

HOWL Financial Statement

HOWL Analyst ratings

HOWL Analysis & performance metrics

HOWL Company profile

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company,…

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead…

HOWL Management team

Name

Position

Steven H. Bloom R.Ph.

Chief Business Officer

Chulani Karunatilake Ph.D.CTO

Chief Technology Officer

Daniel J. Hicklin Ph.D.CEO

Founder, Chief Executive Officer, President, Secretary & Director

Timothy W. Trost CPACFO

Chief Financial Officer, Treasurer & Assistant Secretary

Randi Isaacs M.D.

Chief Medical Officer

William Winston Ph.D.

Senior Vice President of Research

Name

Position

Steven H. Bloom R.Ph.

Chief Business Officer

Chulani Karunatilake Ph.D.CTO

Chief Technology Officer

Daniel J. Hicklin Ph.D.CEO

Founder, Chief Executive Officer, President, Secretary & Director

Timothy W. Trost CPACFO

Chief Financial Officer, Treasurer & Assistant Secretary

Randi Isaacs M.D.

Chief Medical Officer

William Winston Ph.D.

Senior Vice President of Research

Management Team

Steven H. Bloom R.Ph.

Chief Business Officer

Chulani Karunatilake Ph.D.CTO

Chief Technology Officer

Daniel J. Hicklin Ph.D.CEO

Founder, Chief Executive Officer, President, Secretary & Director

Timothy W. Trost CPACFO

Chief Financial Officer, Treasurer & Assistant Secretary

Randi Isaacs M.D.

Chief Medical Officer

William Winston Ph.D.

Senior Vice President of Research

Management

Steven H. Bloom R.Ph.

Chief Business Officer

Chulani Karunatilake Ph.D.CTO

Chief Technology Officer

Daniel J. Hicklin Ph.D.CEO

Founder, Chief Executive Officer, President, Secretary & Director

Timothy W. Trost CPACFO

Chief Financial Officer, Treasurer & Assistant Secretary

Randi Isaacs M.D.

Chief Medical Officer

William Winston Ph.D.

Senior Vice President of Research

Total 6 executives

HOWL Frequently asked questions

What is Werewolf Therapeutics, Inc. (HOWL) Stock Price?

Current stock price of Werewolf Therapeutics, Inc. (HOWL) stock is $1.000. The stock price is +4.26% higher in the session. The intraday range can be seen from this page. Volume of Werewolf Therapeutics, Inc. (HOWL) stock is 1.28M.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Werewolf Therapeutics, Inc. (HOWL) stock price going up or down today?

The stock price of Werewolf Therapeutics, Inc. (HOWL) can change with earnings, company news, and overall market sentiment. Werewolf Therapeutics, Inc. operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Werewolf Therapeutics, Inc. stock expensive at its current price?

Whether Werewolf Therapeutics, Inc. looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for HOWL on this page is -1.31. EPS on this page is -0.76. Compare those figures with peers and growth expectations before deciding if the current Werewolf Therapeutics, Inc. price is justified.

How has the stock price of Werewolf Therapeutics, Inc. (HOWL) performed historically?

Historical performance for Werewolf Therapeutics, Inc. (HOWL) is shown on the price chart on this page. Review multi-period moves alongside volume to see how HOWL reacted to past earnings and market events.

Should I buy Werewolf Therapeutics, Inc. (HOWL) stock, at this price?

Buying Werewolf Therapeutics, Inc. (HOWL) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.